HanchorBio Founder Dr. Scott Liu Invited to Moderate at BIOCHINA 2026

BIOCHINA 2026 (11th BIOCHINA Annual Conference & Expo) will be held from March 12–14, 2026 in Suzhou, China. Dr. Scott Liu, Founder, Chairman and Chief Executive Officer of HanchorBio Inc., has been invited to attend the conference and will serve as a roundtable moderator at the Antibody Drug Innovation & Development Forum, as well as participate as a featured interview and discussion speaker.

Event Information

• Event Name: BIOCHINA 2026 (11th BIOCHINA Annual Conference & Expo)

• Date: March 12–14, 2026

• Location: Suzhou, China

• Official Link:
  https://event.morebio.cn/schedule-pc/125cc224-2393-45d3-987f-7f28004966c9/special/1520

Forum & Interview Details

• Forum: Antibody Drug Innovation & Development Forum

  • Featured Interview & Discussion Speaker

• Interview Topic:
  “Focused Strategies in Specialized Segments — Insights from BD Transactions on the Positioning and Collaborative Strategy of Bispecific and Multispecific Antibody Innovation”

Dr. Scott Liu will share perspectives drawn from his extensive experience in global licensing, innovative antibody development, and corporate strategy, offering insights into how BD transactions shape competitive positioning and collaborative ecosystems in the dual/multi-antibody landscape.

About BIOCHINA

Founded in 2016, BIOCHINA is dedicated to building a global platform for collaboration and exchange within the biopharmaceutical industry. It has grown into one of the most influential life sciences industry events in the Asia-Pacific region.

Expected scale of BIOCHINA 2026:

• 30,000+ attendees

• 40+ countries and regions represented

• 850+ speakers

• 250+ sub-forums

• 3,000+ partnering meetings

• 400+ exhibitors

The conference will bring together leaders from biotechnology, pharmaceutical companies, research institutions, and the investment community to explore advances in biologics innovation, clinical development, and international collaboration.

Speaker Profile

Dr. Scott Liu

Founder, Chairman & Chief Executive Officer of HanchorBio Inc.

Dr. Scott Liu is the Founder, Chairman and CEO of HanchorBio, a clinical-stage global biotechnology company focused on the development of innovative immuno-oncology therapeutics. The Company leverages its proprietary Fc-Based Designer Biologics (FBDB) platform to engineer multifunctional fusion biologics targeting diverse mechanisms of action, aiming to reactivate the immune system to treat multiple cancers.

HanchorBio’s lead candidate, HCB101, developed using the FBDB platform, has demonstrated efficacy and safety across cell-based, murine, and non-human primate studies. It is currently undergoing global Phase 1 clinical trials (including the U.S., Mainland China, and Taiwan), with encouraging preliminary observations in patients. The program has progressed into Phase 1b/2 clinical studies in 2025, targeting gastric cancer, triple-negative breast cancer, and head and neck cancers.

The Company’s second program, HCB301, a tri-functional fusion biologic, is also in Phase 1 clinical trials in the U.S. and Mainland China, with early dose cohorts demonstrating favorable safety. Additional oncology and autoimmune biologics are advancing through preclinical and clinical development.

Prior to founding HanchorBio, Dr. Liu was a global partner of Fosun International and co-founder, President, and CEO of Shanghai Henlius Biotech (HKEX: 2696), a commercial-stage global biopharmaceutical company. Under his leadership, Henlius advanced over 30 product development programs—including biosimilars, novel monoclonal antibodies, and bispecific antibodies—and successfully launched multiple antibody products in China and Europe.

Dr. Liu brings more than 30 years of experience in corporate strategy, portfolio management, quality operations, GMP manufacturing, and regulatory affairs. He previously held senior positions at United Biomedical, Bristol-Myers Squibb, and Amgen. He earned his Ph.D. in Biology from Purdue University and completed postdoctoral research at Stanford University. He also served as Associate Professor at National Sun Yat-sen University in Taiwan.

We Look Forward to Connecting in Suzhou

HanchorBio warmly invites industry partners and colleagues to join BIOCHINA 2026. We look forward to engaging with global experts, exchanging forward-looking insights, and exploring new collaboration opportunities in Suzhou.

漢康生技創辦人暨董事長兼執行長劉世高博士受邀出席 BIOCHINA 2026 並擔任圓桌主持人暨主講嘉賓

BIOCHINA 2026（第十一屆）易貿生物產業展覽將於 2026年3月12日至3月14日 在中國大陸蘇州舉行。漢康生技創辦人、董事長暨執行長 劉世高博士 受邀出席本屆盛會，並將擔任「抗體藥物創新開發論壇」圓桌會議主持人，同時參與專題訪談與分享，與全球產業領袖共同探討抗體藥物創新與產業合作策略。

會議資訊

• 會議名稱：BIOCHINA 2026（第十一屆）易貿生物產業展覽

• 舉辦日期：2026年3月12日（四）至3月14日（六）

• 舉辦地點：中國蘇州

• 官方連結：
  https://event.morebio.cn/schedule-pc/125cc224-2393-45d3-987f-7f28004966c9/special/1520

論壇與訪談資訊

• 論壇名稱：抗體藥物創新開發論壇

• 訪談主題：
  〈細分賽道聚焦——從 BD 交易看雙／多特異性抗體創新藥布局與協同合作戰略〉

劉博士將結合其於跨國授權合作、創新抗體開發與企業戰略規劃之實務經驗，分享對雙／多抗創新藥布局與產業協同合作之觀察與洞見。

關於 BIOCHINA

BIOCHINA 創辦於2016年，致力於建構全球生物產業交流合作平台，現已成為亞太地區具高度影響力之生物產業盛會之一。

BIOCHINA 2026 現場將邀請：

• 30,000+ 參會觀眾

• 40+ 海外國家與地區

• 850+ 演講嘉賓

• 250+ 分論壇場次

• 3,000+ 商務媒合會議

• 400+ 參展廠商

本屆大會將匯聚全球生技製藥企業、研發機構與投資界代表，全面探討生物醫藥創新技術、臨床開發進展與國際合作契機。

主講嘉賓簡介

劉世高博士為漢康生技創辦人、董事長暨執行長。公司為一家臨床開發階段之全球性生技企業，專注於腫瘤免疫創新藥物研發，並以專有「基於 Fc 設計的生物製藥（FBDB）」技術平台為核心，開發多靶向融合蛋白生物藥，致力於重新啟動免疫系統以對抗多種癌症疾病及自體免疫疾病。

首項基於 FBDB 平台開發之融合蛋白生物藥 HCB101，已完成多項臨床前研究並於全球（包括美國、中國大陸與台灣）展開臨床一期試驗，並觀察到正向臨床成果，現已推進至1b/2期臨床試驗。第二項三功能融合蛋白生物藥 HCB301 亦於美國與中國大陸展開臨床1a期試驗，並證實初步安全性。多項後續腫瘤免疫與自體免疫疾病創新藥物正持續推進中。

劉博士於企業策略規劃、產品組合布局、品質營運與國際監管事務方面擁有逾30年經驗。曾為上海復宏漢霖聯合創辦人、總經理暨執行長，領導多項生物相似藥與創新抗體藥物開發與上市，並具備豐富國際授權與合作經驗。

誠摯邀請 共同參與

漢康生技誠摯邀請產業先進蒞臨 BIOCHINA 2026 盛會，與全球專家共襄盛舉。